BURNABY, BC, March 1, 2013 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX-V: WBI), announced today that Mrs. Lijuan Pang has resigned as a
director of the Company effective March 1, 2013.
The Company has valued the contribution of Mrs. Pang as a director of
the Company over the past one and half years and wishes her success in
her future endeavours.
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune diseases and
cancer. For a more complete business and financial profile of the
Company, interested parties are encouraged to visit the Company's
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that
include our belief as to the potential of our products. Certain risks
and uncertainties such as our ability to successfully commercialize the
products could cause the Company's actual results to differ materially
from those in the forward-looking statements.
SOURCE: Welichem Biotech Inc.
For further information:
Liren Tang, President and Chief Executive Officer of the Company: Tel.: (604) 432-1703, Email: firstname.lastname@example.org